Skip to content

SG&A at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.18B+5.0%
Danaher logo
DanaherDHR
$1.86B+0.1%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$676.2M+69.5%
WAT
Waters CorporationWAT
$387M+122%
Agilent Technologies logo
Agilent TechnologiesA
$465M+2.4%
Illumina logo
IlluminaILMN
$272M+1.9%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's SG&A?
Revvity (RVTY) reported SG&A of $253.88M in Q1 2026.
How has Revvity's SG&A changed year-over-year?
Revvity's SG&A increased by 1.7% year-over-year, from $249.72M to $253.88M.
What is the long-term trend for Revvity's SG&A?
Over 4 years (2021 to 2025), Revvity's SG&A has grown at a -2.6% compound annual growth rate (CAGR), from $1.1B to $991.89M.
What does SG&A mean?
The overhead costs required to run the business, excluding direct production costs.
How do you interpret SG&A?
A decrease relative to revenue suggests improved operational efficiency, while a significant increase may indicate aggressive expansion or bloated administrative costs.
How does SG&A compare across companies?
Commonly benchmarked against revenue to determine operating leverage; peers in the life sciences sector typically manage this as a percentage of sales.